What is the budget impact of funding Zilver PTX DESs in treating de novo or restenotic lesions in above-the-knee peripheral arterial disease from the perspective of the Ontario Ministry of Health and Long-Term Care? [...] In November 2014, the Canadian Agency for Drugs and Technologies in Health published a brief report on the Zilver PTX DES for the treatment of PAD of the femoropopliteal vessels in Issues in Emerging Health Technologies. [...] Comparison of Zilver PTX DESs With PTA In the primary randomization of the Zilver PTX RCT, the clinical benefit index at 12 months was significantly higher in the DES group (88.3%) than in the PTA group (75.8%) (P < 0.001).